DGT-SM-Cancer2

DGT-SM-Cancer2 is an undisclosed small-molecule targeted radiotherapeutic being developed by dGenThera. It is currently in the lead optimization stage of preclinical development. The drug is designed to target specific membrane transporters that are overexpressed in a particular, undisclosed cancer type (referred to as "Cancer 2"). By binding to these transporters, the small molecule delivers a radioactive payload directly to the tumor cells, providing localized radiation therapy while minimizing systemic exposure and off-target toxicity. The specific identity of the transporter target and the radioactive isotope used in this candidate have not been publicly disclosed.

Other names

dGenThera-Transporter(s)-small molecule-targeted radiotherapeutic-Cancer 2 (undisclosed)